Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

May 14, 2009 09:39 ET

COTI-2 in Combination With Taxol® (Paclitaxel) Is Superior to Treatment With Paclitaxel Alone in an Animal Model of Aggressive Human Endometrial Cancer

LONDON, ONTARIO--(Marketwire - May 14, 2009) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from animal experiments carried out at a prominent American cancer research facility. The following results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional first line single agent therapy for the treatment of endometrial cancer:

- Up to 40% complete tumor regression (weight equals 0 mg) was observed in the combination treatment groups (paclitaxel plus COTI-2) while no complete regressions (0%) occurred in the paclitaxel alone treatment group.

- The combination treatment with paclitaxel plus COTI-2 was associated with a statistically significant improvement in absolute survival compared with the paclitaxel group.

- The tumor growth inhibition was 71.5% greater in the paclitaxel plus COTI-2 treated animals compared with paclitaxel alone.

- Combination treatments were well tolerated.

"We are delighted to see that intravenous COTI-2 in combination with paclitaxel showed superior treatment results compared to paclitaxel alone as measured by an improved tumor regression rate, an improved survival rate and delayed tumor growth in an animal model of aggressive human endometrial cancer (AN3-CA). These results are significant as they add to the impressive data set of COTI-2, showing efficacy against multiple cancers and low toxicity," said Dr. Wayne Danter, President and Chief Scientific Officer (CSO) of Critical Outcome Technologies Inc. (COTI).

COTI will present this new data to parties who have expressed interest in a commercial partnership related to COTI-2, including executives from several major pharmaceutical organizations, at BIO taking place May 18-21, 2009 in Atlanta, GA. "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2," said Mr. Michael Cloutier, Chief Executive Officer (CEO) of COTI. COTI will be represented at BIO by Mr. Michael Cloutier, CEO, Dr. Wayne Danter, President and CSO and Mr. Michael Barr, Director of Business Development and Marketing.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and preclinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds are under active development: small cell lung cancer, HIV integrase inhibitors, acute adult leukemia, multiple sclerosis and colorectal cancer.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Critical Outcome Technologies Inc.
    Michael Barr
    Director of Business Development and Marketing